LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

United Therapeutics Corp

Cerrado

SectorSalud

283.95 -0.07

Resumen

Variación precio

24h

Actual

Mínimo

282.08

Máximo

287.36

Métricas clave

By Trading Economics

Ingresos

21M

322M

Ventas

59M

794M

P/B

Media del Sector

11.556

50.291

BPA

6.63

Margen de beneficio

40.559

Empleados

1,305

EBITDA

-41M

383M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+30.4% upside

Dividendos

By Dow Jones

Próximas Ganancias

30 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-4.2B

13B

Apertura anterior

284.02

Cierre anterior

283.95

Noticias sobre sentimiento de mercado

By Acuity

93%

7%

363 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

United Therapeutics Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

7 oct 2024, 15:14 UTC

Principales Movimientos del Mercado

Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal

28 ene 2025, 10:30 UTC

Principales Noticias

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

Comparación entre iguales

Cambio de precio

United Therapeutics Corp Esperado

Precio Objetivo

By TipRanks

30.4% repunte

Estimación a 12 meses

Media 370.44 USD  30.4%

Máximo 432 USD

Mínimo 314 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para United Therapeutics Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

10 ratings

7

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

292.345 / 309.245Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

363 / 380 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.